Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Catalytic antibodies and their applications.

Hanson CV, Nishiyama Y, Paul S.

Curr Opin Biotechnol. 2005 Dec;16(6):631-6. Epub 2005 Oct 21. Review.

PMID:
16243512
2.

Antibodies as defensive enzymes.

Paul S, Nishiyama Y, Planque S, Karle S, Taguchi H, Hanson C, Weksler ME.

Springer Semin Immunopathol. 2005 Mar;26(4):485-503. Epub 2005 Jan 5. Review.

PMID:
15633014
3.

Prospects for immunotherapeutic proteolytic antibodies.

Zhou YX, Karle S, Taguchi H, Planque S, Nishiyama Y, Paul S.

J Immunol Methods. 2002 Nov 1;269(1-2):257-68. Review.

PMID:
12379366
4.

Production and characterization of anti-cocaine catalytic antibodies.

de Prada P, Landry DW.

Methods Mol Biol. 2004;248:495-501. No abstract available.

PMID:
14970516
5.

Anticocaine catalytic antibodies have no affinity for RTI compounds: implications for treatment.

Kuhar MJ, Carroll FI, Bharat N, Landry DW.

Synapse. 2001 Aug;41(2):176-8.

PMID:
11400184
6.

Cocaine catalytic antibodies: the primary importance of linker effects.

Matsushita M, Hoffman TZ, Ashley JA, Zhou B, Wirsching P, Janda KD.

Bioorg Med Chem Lett. 2001 Jan 22;11(2):87-90.

PMID:
11206477
7.

The therapeutic potential for catalytic antibodies: from a concept to a promise.

Jones LH, Wentworth P Jr.

Mini Rev Med Chem. 2001 Jul;1(2):125-32. Review.

PMID:
12369978
8.

Anticocaine catalytic antibodies.

Deng SX, de Prada P, Landry DW.

J Immunol Methods. 2002 Nov 1;269(1-2):299-310. Review.

PMID:
12379369
9.

Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions.

Kottilil S, Shin K, Jackson JO, Reitano KN, O'Shea MA, Yang J, Hallahan CW, Lempicki R, Arthos J, Fauci AS.

J Immunol. 2006 Jan 15;176(2):1107-14.

10.

Induction of covalent binding antibodies.

Armentano F, Knight T, Makker S, Tramontano A.

Immunol Lett. 2006 Feb 28;103(1):51-7. Epub 2005 Oct 27.

PMID:
16297987
11.

Substrate-assisted antibody catalysis.

Deng S, Bharat N, de Prada P, Landry DW.

Org Biomol Chem. 2004 Feb 7;2(3):288-90. Epub 2003 Dec 24.

PMID:
14747854
12.

Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde.

Belogurov A Jr, Kozyr A, Ponomarenko N, Gabibov A.

Bioessays. 2009 Nov;31(11):1161-71. doi: 10.1002/bies.200900020. Review.

PMID:
19795406
13.

Complete reaction cycle of a cocaine catalytic antibody at atomic resolution.

Zhu X, Dickerson TJ, Rogers CJ, Kaufmann GF, Mee JM, McKenzie KM, Janda KD, Wilson IA.

Structure. 2006 Feb;14(2):205-16.

14.

Role of gp120 in dendritic cell dysfunction in HIV infection.

Chougnet C, Gessani S.

J Leukoc Biol. 2006 Nov;80(5):994-1000. Epub 2006 Aug 15. Review.

PMID:
16912071
15.

Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease.

Steinitz M.

Expert Opin Biol Ther. 2008 May;8(5):633-42. doi: 10.1517/14712598.8.5.633 . Review.

PMID:
18407766
16.

The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection.

Djordjevic A, Veljkovic M, Antoni S, Sakarellos-Daitsiotis M, Krikorian D, Zevgiti S, Dietrich U, Veljkovic N, Branch DR.

Curr HIV Res. 2007 Sep;5(5):443-8.

PMID:
17896963
18.

Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins.

Lambert MP, Velasco PT, Viola KL, Klein WL.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):65-81. Review.

PMID:
19275637
19.

Novel approaches for immunotherapeutic intervention in Alzheimer's disease.

Vasilevko V, Cribbs DH.

Neurochem Int. 2006 Jul;49(2):113-26. Epub 2006 Jun 12. Review.

PMID:
16765487
20.

Identification and characterization of single chain anti-cocaine catalytic antibodies.

McKenzie KM, Mee JM, Rogers CJ, Hixon MS, Kaufmann GF, Janda KD.

J Mol Biol. 2007 Jan 19;365(3):722-31. Epub 2006 Nov 3.

Supplemental Content

Support Center